---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-180771"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:01:15.845914+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences Q2 net loss $0.96/share; $106.1M cash; three FB102 trials on track for 2026 data

## Summary
- Net loss per share $(0.96) vs $(6.78) YoY; R&D expenses $8.6M up from $5.7M driven by clinical trials.
- Cash and cash equivalents $106.1M; raised $69.9M net in June 2025 offering plus $1.7M overallotment.
- Phase 2 celiac disease trial dosing; topline data expected 2026; phase 1b vitiligo data 1H26; alopecia areata initiated with 2026 data.
- Shares outstanding: 12.3M common stock and 5.4M pre-funded warrants as of June 30, 2025.

## SEC filing metadata
- accession: 0001193125-25-180771
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312525180771/0001193125-25-180771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312525180771/d939022d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-180771
- JSON: https://secwatch.observer/filing/0001193125-25-180771.json
- Plain text: https://secwatch.observer/filing/0001193125-25-180771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.